Cancers (Oct 2022)

Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort

  • Hyunji Jo,
  • Seri Park,
  • Hye Ryeon Kim,
  • Hongsik Kim,
  • Joohyun Hong,
  • Jeong Eon Lee,
  • Jonghan Yu,
  • Byung Joo Chae,
  • Se Kyung Lee,
  • Jai Min Ryu,
  • Soo-young Oh,
  • Suk Joo Choi,
  • Ji-Yeon Kim,
  • Jin Seok Ahn,
  • Young-Hyuck Im,
  • Eun Mi Nam,
  • Seok Jin Nam,
  • Yeon Hee Park

DOI
https://doi.org/10.3390/cancers14194839
Journal volume & issue
Vol. 14, no. 19
p. 4839

Abstract

Read online

Background: Given that peak age of breast cancer (BC) is younger in Asians than in Western populations, relatively higher prevalence of pregnancy-associated breast cancer (PABC) has been reported. This study aimed to analyze the characteristics and clinical outcomes of PABC in Korea. Methods: We defined PABC as BC diagnosed during pregnancy or in the first postpartum year. We compared the clinicopathological characteristics and BC outcomes between patients with PABC and non-PABC patients in the prospective YBC cohort from Samsung Medical Center. Results: In total, 1492 patients were initially enrolled, and 1364 patients were included, of which 93 had PABC (6.8%). The median age of patients with PABC was 34 years. Hormone receptor expression was lower (64.6% vs 74.6%) and frequency of HER2 overexpression was higher (26.9% vs 17.6%) in patients with PABC than in non-PABC patients. The 5-year overall survival (OS) rates were 83.2% and 93.4% in patients with PABC and non-PABC patients, respectively (p < 0.001). The 5-year disease-free survival (DFS) rates were 72.2% and 83.8% in PABC and non-PABC patients. Conclusion: Compared to non-PABC patients, patients with PABC had poorer OS and DFS in this prospective cohort. Exploratory biomarker analysis for PABC is warranted.

Keywords